Form 4: Instil Bio Director Gwendolyn Binder Receives Stock Options

Director Gwendolyn Binder was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.

Summary

• Director Gwendolyn Binder acquired 6,500 stock options in Instil Bio, Inc. (TIL) on June 11, 2026.
• The options have an exercise price of $7.93 per share.
• The options are set to expire on June 10, 2036.
• Vesting occurs in 12 substantially equal monthly installments starting July 11, 2026, with full acceleration upon specific events like a change in control or death.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility may impact the future value of the granted options.
• The value of the options is contingent upon the director's continued service to the company.

Future Outlook

The options vest over a 12-month period, indicating a short-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized during long-term drug development cycles.

Comparison to Industry Standards

• The grant of 6,500 options is consistent with standard director compensation packages for small-cap biotechnology firms.
• Vesting schedules of 12 months are relatively aggressive compared to the typical 3-4 year vesting periods seen in larger pharmaceutical companies.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Director to continue service to satisfy vesting requirements.
• Potential future exercise of options by the director.

Key Dates

Keywords

Instil Bio, TIL, Form 4, Stock Options, Insider Trading, Director Compensation